<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03790709</url>
  </required_header>
  <id_info>
    <org_study_id>ANAVEX2-73-AD-004</org_study_id>
    <nct_id>NCT03790709</nct_id>
  </id_info>
  <brief_title>ANAVEX2-73 for Treatment of Early Alzheimer's Disease</brief_title>
  <official_title>A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-week Safety and Efficacy Trial of ANAVEX2-73 for the Treatment of Early Alzheimer's Disease (AD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anavex Life Sciences Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Anavex Australia Pty Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anavex Germany GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anavex Canada Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Anavex Life Sciences Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2b/3 48-week study to evaluate the effects of ANAVEX2-73 on cognition and function
      after 48 weeks of daily treatment. Additional outcome measures include refined measures of
      sleep, behavioral and psychological symptoms typically observed in AD, changes in daily
      functioning of participants and changes in caregiver burden, as well as changes in quality of
      life measures of both, patients and caregivers during treatment with ANAVEX2-73.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2b/3 48-week study to evaluate the effects of ANAVEX2-73 on cognition and
      function after 48 weeks of daily treatment. Additional outcome measures include refined
      measures of sleep, behavioral and psychological symptoms typically observed in AD, changes in
      daily functioning of participants and changes in caregiver burden, as well as changes in
      quality of life measures of both, patients and caregivers during treatment with ANAVEX2-73.
      In addition, safety assessments, pharmacokinetic (PK) assessments and collections of CSF and
      blood markers of AD pathophysiology before and after treatment will be performed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 3, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized 1:1:1 to two different ANAVEX2-73 doses or placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>There will be blinding procedures for this study. Capsules will be indistinguishable from active ingridient containing capsules.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>ADAS-Cog (Alzheimer Disease Assessment Scale-Cognition)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change from baseline to week 48 in cognition according to the Alzheimer Disease Assessment Scale-Cognition (ADAS-Cog) compared to placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ADCS-ADL (Activities of Daily Living)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes from baseline to week 48 in ability to perform daily activities according to the Activities of Daily Living Scale (ADCS-ADL) compared to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.03</measure>
    <time_frame>48 weeks</time_frame>
    <description>Assess the safety and tolerability of ANAVEX2-73 compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDR-SB (Clinical Dementia Rating Scale Sum of Boxes)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change from baseline to week 48 on Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RSCAQ sleep score</measure>
    <time_frame>Weeks 0, 4, 12, 24, 36, and 48</time_frame>
    <description>To evaluate whether ANAVEX2-73 improves sleep continuity as assessed on a serial basis (weeks 0, 4, 12, 24, 36, and 48) with a questionnaire that assess reported sleep continuity (RSCAQ)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with change of brain volume assessed by MRI</measure>
    <time_frame>48 weeks</time_frame>
    <description>Structural (and optional ASL) MRI scan assessments characteristic for AD pathophysiology from baseline and compared to placebo at +48 weeks</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood assessment</measure>
    <time_frame>48 weeks</time_frame>
    <description>Blood assessment from baseline and compared to placebo at +48 weeks: Abeta40, Abeta42, T-tau, NFL, YKL-40, BACE1 concentration</description>
  </other_outcome>
  <other_outcome>
    <measure>CSF assessment</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes in CSF parameters (Abeta40, Abeta42, T-tau, P-tau, NFL, YKL-40, neurogranin, BACE1 concentration) characteristic for AD pathophysiology from baseline and compared to placebo at
+48 weekstreatment differences within subgroups will be performed</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with pre-specified genetic variants</measure>
    <time_frame>48 weeks</time_frame>
    <description>AD relevant pre-specified genetic variants will be assessed. Statistical testing of treatment differences within subgroups will be performed</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>High dose ANAVEX2-73</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose active once daily orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid dose ANAVEX2-73</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mid dose active once daily orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo oral capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo dose once daily orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose ANAVEX2-73</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>High dose ANAVEX2-73</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mid dose ANAVEX2-73</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>Mid dose ANAVEX2-73</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>Placebo oral capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 60 to 85 years, inclusive, with a NIA-AA diagnosis of mild cognitive
             impairment (MCI) due to AD or early stage mild dementia due to AD. AD diagnosis should
             be made by an appropriately qualified medical specialist and AD pathology should be
             confirmed by either:

               1. Historical records of amyloid CSF assessment or

               2. Historical records of amyloid PET scan or

               3. If neither historical records are available, then AD pathological diagnosis
                  confirmation should be offered at screening:

             i. CSF collection or ii. Amyloid PET iii. Past medical records of MRI or CT are
             optional.

          -  Mini Mental State Examination (MMSE) score between 20-28, inclusive.

          -  Free Recall score â‰¤17 or Total Recall score &lt;40 on the Free and Cued Selective
             Reminding Test (FCSRT).

          -  Participants are either outpatients, or residents of an assisted-living facility.
             Participant has a designated study partner, who spends at least 10hrs per week with
             the participant, in order that assessments e.g. carer burden instruments are completed
             with true knowledge of the participant.

          -  No suicidal ideation of type 4 or 5 in the Columbia Suicide Severity Rating Scale
             (C-SSRS) in the past 3 months (i.e. active suicidal thought(s) with intent but without
             specific plan, or active suicidal thought(s) with plan and intent) OR suicidal
             behavior in the past 2 years (i.e. actual attempt, interrupted attempt, aborted
             attempt, or preparatory acts or behavior).

          -  Confirmation from the participant that, if of childbearing potential is not pregnant
             through urine pregnancy testing.

        Exclusion Criteria:

          -  Patients who have a progressive medical or neurological condition that in the opinion
             of the investigator would interfere with the conduct of the study. Exception: If
             diagnosed with seizures, must be on stable anti-seizure medication for at least 3
             months prior to screening.

          -  Current clinically significant systemic illness that is likely to result in
             deterioration of the patient's condition or affect the patient's safety during the
             study.

          -  History or clinically evident stroke or clinically significant carotid or
             vertebrobasilar stenosis or plaque.

          -  History of neurologic (e.g. stroke, traumatic brain injury) or psychiatric condition
             that the investigator deems may interfere with interpretability of data.

          -  History of untreated thyroid disorder, Type 1 diabetes, and insulin dependent or
             uncontrolled Type II diabetes, as determined by the investigator (e.g.
             non-insulin-controlled Type II diabetes, whose HbA1c value is higher than 8.0%).

          -  Body Mass Index (BMI) &gt; 30.

          -  History of clinical hepatic dysfunction.

          -  Current symptomatic and unstable/uncontrolled gastrointestinal, hepatic, renal,
             respiratory, cardiovascular, metabolic, immunological, hematological or hormonal
             disorders.

          -  Indication of liver disease, defined by serum levels of ALT (SGPT), AST (SGOT), or
             alkaline phosphatase above 3x upper limit of normal (ULN) as determined during
             screening.

          -  Significant history of drug addiction (with the exception of nicotine dependence) or
             abuse (including alcohol, as defined in DSM-V or in the opinion of the investigator)
             within the last two years prior to informed consent, or a positive urine drug screen
             for cocaine, opioid, phencyclidine (PCP), amphetamine or marijuana at screening.
             Prescription medication yielding a positive drug screen are acceptable except for
             tricyclic antidepressants (e.g. Amitriptyline, Amoxapine, Desipramine, (Norpramin)
             Doxepin, Imipramine (Tofranil), Nortriptyline (Pamelor), Protriptyline (Vivactil),
             Trimipramine (Surmontil)).

          -  Clinically significant infection within the last 30 days prior screening (e.g.,
             chronic persistent or acute infection, urinary tract infections (UTI)).

          -  Treatment with immunosuppressive medications (e.g., systemic corticosteroids) within
             the last 90 days (topical and nasal corticosteroids and inhaled corticosteroids for
             asthma are permitted) or chemotherapeutic agents for malignancy within the last 3
             years.

          -  Myocardial infarction within the last year.

          -  History of cancer within the last 3 years, with the exception of basal cell carcinoma
             and non-metastatic squamous cell carcinoma of the skin and prostate cancer with
             currently normal PSA.

          -  Other clinically significant abnormality on physical, neurological, laboratory, or
             electrocardiogram (ECG) examination (e.g., atrial fibrillation) that could compromise
             the study or be detrimental to the participant.

          -  Hemoglobin &lt; 11 g/dL.

          -  Have any contraindication to MRI scanning, including cardiac pacemaker/defibrillator,
             ferromagnetic metal implants (e.g., in skull and cardiac devices or severe
             claustrophobia).

          -  Smoking &gt; 1 pack of cigarettes per day (as assessed for the 30 days prior to
             screening).

          -  Alcohol use of more than 2 drinks per day.

          -  Current use of over-the-counter (OTC) supplements or nutraceuticals unless they are on
             stable dose for at least 3 months prior to screening and are documented in the eCRF.

          -  Use of over the counter (OTC) or prescription medication for sleep on 2 or more
             occasions per week.

          -  Being treated with psychoactive medications on a stable dose for less than 3 month.

          -  Any prior exposure to ANAVEX2-73.

          -  Individuals enrolled in previous AD clinical trial involving an investigational drug
             treatment less than 3 months ago (longer than 3 month ago allowed).

          -  Any known hypersensitivity to any of the excipients contained in the study drug
             formulation.

          -  Any other criteria (such as a clinically significant screening blood test result),
             which in the opinion of the Investigator causes the participant not to qualify for the
             study.

          -  Evidence of cerebrovascular dementia with a Hachinski score of 4 or more.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>844-689-3939</phone>
    <email>alz@anavex.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Central Coast Neurosciences Research</name>
      <address>
        <city>Central Coast</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Sturm, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hornsby (Northern Sydney Health)</name>
      <address>
        <city>Hornsby</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Kurrle, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>KaRa MINDS</name>
      <address>
        <city>Macquarie Park</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosalyn Lai, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Vincent Hospital Sydney</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce J Brew, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Sydney</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Lewis, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gold Coast Memory Disorders Clinic</name>
      <address>
        <city>Southport</city>
        <state>Quennsland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Morris, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Adelaide Hospital (RAH) and The Queen Elizabeth Hospital (TQEH)</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Short, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Penninsula Therapeutic and Research Group</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Grunfeld, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Geelong Private Medical Centre</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alastair Mander, A/Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Delmont Private Hospital</name>
      <address>
        <city>Glen Iris</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Drysdale, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hammond Care</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Macfarlane, A/Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alfred Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terrence O'Brien, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Woodward, A/Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monash Alfred Psychiatry Research Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Wise, A/Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital (RMH)</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Brodtmann, A/Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>McCusker</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sneha Bharadwaj, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brain Research Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sterre Malou Rutgers, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brain Research Center</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Dautzenberg, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MAC Clinical Research</name>
      <address>
        <city>Teesside</city>
        <state>County Durham</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adeyemi Adeyi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine Pennington, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glasgow Memory Clinic</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Lynch, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cognition Health</name>
      <address>
        <city>Guildford</city>
        <state>Surrey</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Mannering, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MAC Clinical Research</name>
      <address>
        <city>Barnsley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Victoria Lynch, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cognition Health</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J. Emer MacSweeney, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MAC Clinical Research</name>
      <address>
        <city>Blackpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Abimbola Babajide, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MAC Clinical Research</name>
      <address>
        <city>Cannock</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kim-Claire Tabner, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MAC Clinical Research</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sam Leving, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MAC Clinical Research</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chigomezgo Munthali, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cognition Health</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. Emer MacSweeney, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imperial College</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard Perry, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>King's College</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chris Kalafatis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MAC Clinical Research</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nubli Mustapa, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cognition Health</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephen Pearson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern Health NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Saif Sharif, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 24, 2018</study_first_submitted>
  <study_first_submitted_qc>December 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2019</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

